Genelux (NASDAQ:GNLX) Issues Earnings Results

20 Mar 2026, 13:34 by Danessa Lincoln · The Markets Daily

Genelux (NASDAQ:GNLX – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02), FiscalAI reports. The business had revenue of $0.01 million during the quarter.

Genelux Trading Down 4.7%

NASDAQ GNLX opened at $2.42 on Friday. Genelux has a 1-year low of $1.99 and a 1-year high of $8.53. The company has a 50 day moving average of $2.69 and a 200-day moving average of $4.15. The firm has a market cap of $92.12 million, a price-to-earnings ratio of -2.81 and a beta of 0.15.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on GNLX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating on shares of Genelux in a research report on Monday, January 5th. Finally, Wall Street Zen lowered Genelux from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Read Our Latest Analysis on Genelux

Insider Activity at Genelux

In related news, Director John Thomas sold 10,000 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $2.90, for a total transaction of $29,000.00. Following the sale, the director directly owned 482,784 shares in the company, valued at $1,400,073.60. This represents a 2.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Genelux

A number of institutional investors and hedge funds have recently bought and sold shares of GNLX. Private Management Group Inc. acquired a new stake in shares of Genelux in the second quarter valued at $33,000. Jefferies Financial Group Inc. acquired a new position in Genelux during the 4th quarter worth about $48,000. Squarepoint Ops LLC acquired a new position in Genelux during the 4th quarter worth about $52,000. Raymond James Financial Inc. grew its holdings in Genelux by 22.6% during the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after acquiring an additional 5,333 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Genelux during the 2nd quarter worth about $92,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

About Genelux

(Get Free Report)

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.